Clinical trial · Observational
Descriptive Observational Study ALK-2016-CPHG
CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.
NCT03718117CI-TRIAL-00081111ALK2016CPHGcompletedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Descriptive Observational Study. Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALK Gene Rearrangement or ROS1 Gene Rearrangement | — | UNRESOLVED | — |
| Crizotinib | — | UNRESOLVED | — |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (23)
- measure
- Age: Line of Treatment
- timeFrame
- Baseline
- measure
- Body Weight: Line of Treatment and Gene Rearrangement
- timeFrame
- Baseline
- description
- Body weight in kilograms (kg) measured at baseline were reported.
- measure
- Body Mass Index (BMI): Line of Treatment and Gene Rearrangement
- timeFrame
- Baseline
- description
- BMI was obtained by dividing body weight in kilograms (kg) by height in meters square (m\^2).
- measure
- Gender: Line of Treatment
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria * Age ≥ 18 years * Locally advanced or metastatic NSCLC * Patient ALK gene rearrangement or ROS1 gene rearrangement * Patient having initiated in the previous 3 months or patient initiating crizotinib treatment regardless of the line of treatment * Patient followed up by a physician in a hospital pulmonary medicine department * Subject of reproductive age, using an effective method of contraception * Patient informed verbally and in writing on the study and having consented to his/her personal data being collected within the scope of the study. Non-inclusion criteria * Patient included within the scope of an interventional therapeutic trial * Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement * Patient not available for follow-up throughout the duration of the study * Patient deemed to be incapable of responding to the study questions for linguistic, cognitive or organisational reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.